REPLICEL LIFE SCIENCES INC. | CIK:0001205059 | 3

  • Filed: 5/11/2018
  • Entity registrant name: REPLICEL LIFE SCIENCES INC. (CIK: 0001205059)
  • Generator: Compliance Xpressware
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/0001062993-18-002112-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1205059/000106299318002112/repcf-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001205059
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory

      d)

    Impairment of Non-Financial Assets

         
       

    Other non-financial assets are subject to impairment tests whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. Where the carrying value of an asset exceeds its recoverable amounts, which is the higher of value in use and fair value less costs to sell, the asset is written down accordingly.

         
       

    Where it is not possible to estimate the recoverable amount of an individual asset, the impairment test is carried out on the asset’s cash-generating unit, which is the lowest group of assets in which the asset belongs for which there are separately identifiable cash inflows that are largely independent of the cash inflows from other assets. The Company has one cash-generating unit for which impairment testing is assessed.

         
       

    An impairment loss is charged to the profit or loss, except to the extent it reverses gains previously recognized in other comprehensive loss/income.